Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence

Exclusion Criteria

• •Cirrhosis of the liver
• •Patients with significant medical conditions such as cancer, HIV, epilepsy, chronic respiratory failure, renal failure, etc.
• •Non-compatible health conditions (at the discretion of the investigator)
• •The following psychiatric conditions as defined by DSM-5 criteria: schizophrenic disorder, persistent delusional disorder, schizophreniform disorder, schizoaffective disorder, bipolar disorder, autism spectrum disorder identified using the Mini International Neuropsychiatric Interview version 7.0.2 (MINI 7.0.2)
• •Suicidal state identified using MINI 7.0.2
• •Dependence on substances or drugs other than benzodiazepines and nicotine (dependence will be identified through the use of MINI 7.0.2)
• •History of baclofen use for all indications
• •Unauthorized combination therapies will be: pregabalin, topiramate, ketamine, sodium oxybate, gabapentin, valproic acid, sodium valproate, melatonin, buspirone, hydroxyzine, propranolol, bisoprolol, etifoxin, carbamazepine, clonidine, paroxetine, all neuroleptic/antipsychotic class therapies, and tricyclic antidepressants
• •Pregnant or nursing women
• •Hypersensitivity to baclofen or microcrystalline cellulose.
• •Participants under guardianship
• •Patients who need to drive and/or use machines during the 1-week dose escalation phase